SIOUX FALLS, SD – 12-19-2017 (Press Release Jet) — Kasten Inc. (OTC:KAST) d/b/a DAKOTA Life Sciences has obtained exclusive global licensing and commercial development rights to a First-in-Class cyclic depsipeptide new chemical entity for topical and oral prescription antibiotic therapies against methicillin resistant staph aureus (MRSA). This transaction culminates eight months of international efforts by the DAKOTA Life Sciences management team to commercialize more prescription drug candidates and related software technologies to combat global antimicrobial resistance.
The drug, named Lotilibcin, is recognized by the World Health Organization and is listed in the United States National Library of Medicine and in the Chemical Abstract Service (CAS) with Registry Number 169148-84-9.
“We believe that the successful acquisition of these valuable proprietary rights to Lotilibcin drug products is a clear statement of confidence in our ability to bring world class prescription biopharma solutions to global markets” according to Steven Keough, the President of Kasten and CEO of DAKOTA Life Sciences. “This acquisition accelerates our Business Plan goal of providing superior prescription pharmaceuticals to worldwide markets that are urgently in need of new medical solutions to diseases,” according to Keough.
Also, the Company’s global drug development team has completed much of the pre-clinical work on the first prescription product candidate using Lotilibcin. That drug product candidate is designed to serve as a frontline agent against the medical fight that the Centers for Disease Control and Prevention describes as a Serious National Threat to the U.S. healthcare system. DAKOTA Life Sciences’ knowledge and experience with woundcare technologies combines synergistically with the potent Lotilibcin formulations in the global challenge against antimicrobial resistance.
“We are very pleased to be part of a new class of antibiotic that kills MRSA more powerfully than any other known drug” added Keough. In the near future, the Company plans to seek the FDA preferred designation of Qualified Infectious Disease Product for Lotilibcin drug products.
As a result of extensive global efforts in 2017, the Company now has a robust prescription drug product development pipeline, as well as development programs using block chain-based technologies for real time prescription drug security to ensure global reliability of prescription drug products. Additional information concerning the proprietary Lotilibcin and other technologies will be forthcoming as the Company rapidly moves to a fully reporting public market status.
AboutKasten, Inc./DAKOTA Life Sciences
Kasten, Inc. (d/b/a DAKOTA Life Sciences) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions arising both in hospital and community settings. We are principally focused on delivering solutions to those people who are affected by antimicrobial resistance and who need superior pharmaceutical products at affordable prices.
Forward-Looking Statements – This press release contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Kasten, Inc. dba DAKOTA Life Sciences undertakes no obligation to update such statements.
Kasten Inc./DAKOTA Life Sciences
SOURCE Kasten Inc. dba DAKOTA Life Sciences
For the original news story, please visit https://pressreleasejet.com/news/dakota-life-sciences-acquires-rights-to-powerful-prescription-drug-drug-delivery-and-prescription-drug-protection-technologies.html.
Latest posts by Brad Bennett (see all)
- MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California - February 18, 2018
- Mario Lopez Announced As Host To The 'Splash of Love' Gala Fundraiser At Proud Bird Food Bazaar & Events Center - February 18, 2018
- Oxnard Teen, Skilled Boxer Honored as BGCOP's Youth of the Year - February 18, 2018